Karachi: Liven Pharma Limited has reported a series of share transactions executed by its Executive Director, Kaashif Hussain Siddique, according to a disclosure of interest under PSX Regulation 5.6.4. The transactions, dated January 5, 2026, reveal significant sales of the company’s shares by Siddique.

The director sold a total of 25,000 shares, with transactions executed at prices ranging from Rs. 52.51 to Rs. 52.90 per share. The cumulative number of shares held by Siddique following these sales stands at 40.43 million, representing a 43.46% stake in the company.

According to information available from the Pakistan Stock Exchange (PSX), these transactions are categorized under the ‘Ready’ market segment. Each sale involved a form of share certificate classified as ‘CDC’, indicating electronic trading on the Central Depository Company platform.

The sales executed by Siddique include transactions of varying quantities, with the largest single transaction involving 15,000 shares at a rate of Rs. 52.51. Other transactions involved smaller quantities, each ranging between 1,000 to 2,000 shares. The nature of these sales reflects a strategic financial maneuver, as the cumulative percentage of shares held by Siddique experienced a minor move in its percentage value.

As of the disclosed date, the aggregate number of shares held by Siddique remains substantial, solidifying his position as a key shareholder in Liven Pharma Limited. The company’s market activities continue to be closely monitored by stakeholders and market analysts alike, given the influential role of major shareholders in corporate governance and stock market dynamics.